he bowel cleanse for the colonoscopy operation should be conducted using an effective, safe, and tolerable by the patients. However, matching all these criteria is not always possible for every patient. Sodium phosphate -a cleansing agent for colonoscopy, should be carefully administered in the cases where the body fluid/electrolyte balance may be offset; such as of chronic kidney failure, heart failure, old age, diuretic use, angiotensin-converting enzyme (ACE) inhibitor and angiotensin receptor blockers (ARBs) use. It is not always possible to foresee the possible adverse effects of the cleansing agents on healthy individuals. We review the case of severe hypocalcemic tetany that developed in a female patient after the oral administration of two doses of 45 mL sodium phosphate, together with the possible causes.
The Development of Hypocalcemic Tetany
Following the Intestinal Cleanse of a Patient with Vitamin D Deficiency A AB BS S T TR RA AC CT T The most important step of a safe colonoscopy examination is proper intestinal cleansing. There are several different methods that can be applied to the intestinal cleanse. Because of some adverse effects such as electrolyte imbalance, dehydration, allergic reactions, cramping, vomiting, the decision should be made after reviewing the individual characteristics of every patient, which includes age, comorbidities, medication and the fluid/electrolyte balance. was referred to the emergency clinic. The evaluation revealed that the patient was conscious, the respiratory rate was 20 (slight tachypnea), the arterial blood pressure was 110/60 mmHg, the heart peak rate was 68/min, the fingertip oxygen saturation was 97%. The patient had positive Chovestek and Trousseau findings (Figure 1 ). The patient's history did not reveal any known chronic illnesses. There were no prior operations other than the 3 c-sections (the last one one-and-ahalf years ago) and no continuous drug use. It was indicated that the patient had orally taken the two 45 mL doses of sodium phosphate solutions with 500 mL of water the day prior to the planned colonoscopy. She subsequently developed complaints of nausea, followed by numbness in the legs and a tingling sensation all over the body. The patient had clinical findings of tetany and positive Chovestek and Trousseau signs. The laboratory findings were as followed: Creatinine (Crea): 0.55 mg/dL, Calcium (Ca): 5.5 mg/dL, Phosphorus (P): 2.9 mg/dL, Magnesium (Mg): 1.7mg/dL, Sodium (Na): 141 mmol/l, Potassium (K): 3.8 mmol/l; blood gases: pH: 7.390, HCO3: 22.5 (mmol/l), Lactate (Lac): 0.9, Hemoglobin (Hgb): 13.3 g/dL ( Table 1) . The patient had hypocalcemia, hypophosphatemia, and hypomagnesemia. She was IV infused 1000 mg calcium gluconate. The tetany improved after the first dose and the patient was prescribed two more daily doses of calcium gluconate (1000 mg) infusions together with electrolyte controls. Later on, the patient received IV 4 mg of magnesium sulfate for the treatment of hypomagnesemia. The Ca, Mg and P levels were normal after two days. The 25(OH)-vitamin D level was determined to be 2.26 ng/mL. The patient was given an oral vitamin D replacement of 50.000 IU for three days.
The tests revealed that the patient did not have any parathormone (PTH) anomalies (which leads to a predisposition of hypocalcemia) or any pathologies such as kidney failure. It was assumed that the sodium phosphate solution -administered as a preparation for the colonoscopy -led to symptomatic hypocalcemia together with the underly- 
DISCUSSION
Sodium phosphate is one of the osmotic agents that is used for the preparation prior to colonoscopy. It should be used with caution in the cases of acute kidney failure and electrolyte imbalance. 1 The sodium phosphate solutions are reported to cause hyperphosphatemia together with hypocalcemia among patients with kidney disease. However, this condition may be asymptomatically and transiently present among healthy individuals. 2 It is noted that several factors may lead to electrolyte imbalance; such as being female, old age, decreased bowel movement, dehydration, the frequent administration of sodium phosphate. 3, 4 In this case, the female patient had decreased bowel movements. There d no known comorbidities, however, the patient used an insufficient amount of water when orally taking the sodium phosphate solution, which may have contributed to the development of the hypocalcemic outcome. Berker et al. have found that a single dose of 45 mg sodium phosphate led to the development of hypocalcemia and hypophosphatemia in a patient with hypoparathyroidism. 5 In this case, the PTH levels were normal. Despite the lack of literature findings, we believe that the significant vitamin D deficiency may have led to the develop-ment of symptomatic hypocalcemia.
In conclusion sodium phosphate-a cleansing agent for colonoscopy, should be carefully administered in the cases where the body fluid/electrolyte balance may be offset; such as of chronic kidney failure and the use of diuretics. The patients who are observed to be healthy may react adversely to sodium phosphate, especially if there is hypocalcemia. Thus, the Vitamin D levels should be examined and patients must be called for control examination for two days long. A Au ut th ho or rs sh hi ip p C Co on nt tr ri ib bu ut ti io on ns s All authors contributed equally while this study preparing.
